8.52012

Fmoc-Lys(Boc)-OH

Novabiochem^®

• Sinónimos: Fmoc-Lys(Boc)-OH, N-α-Fmoc-N-ε-t.-Boc-L-lysine
• Fórmula empírica (notación de Hill): C₂₆H₃₂N₂O₆
• Número CAS: 71989-26-9
• Peso molecular: 468.54
• UNSPSC Code: 12352209
• EC Index Number: 276-256-4
• NACRES: NA.22
• MDL number: MFCD00037138
• eCl@ss: 32160406

Propiedades

• Quality Level: 400
• product line: Novabiochem^®
• assay: ≥98% (TLC), ≥98.0% (acidimetric), ≥99.0% (HPLC)
• form: powder
• reaction suitability: reaction type: Fmoc solid-phase peptide synthesis
• manufacturer/tradename: Novabiochem^®
• mp: 123-130 °C
• application(s): peptide synthesis
• functional group: Boc, amine
• storage temp.: 2-30°C

Descripción

General description

High purity Fmoc-protected amino acid for research and process production of peptides, with very low levels of dipeptide, free-amino acids and acetic acid impurities. Standard building block for introduction of lysine amino-acid residues by Fmoc SPPS

Associated Protocols and Technical Articles
Fmoc-amino acids for Peptide Production
Cleavage and Deprotection Protocols for Fmoc SPPS

Application

• Pharmacokinetics of Tizanidine in Muscle Spasticity: A comprehensive review on Tizanidine covers its pharmacological advancements and therapeutic applications, particularly focusing on muscle spasticity. This highlights the relevance of high-purity Tizanidine-D₄ hydrochloride in creating precise and reproducible pharmacokinetic profiles (Zhu et al., 2024).


• Stable Isotope-Labeled Tizanidine for Bioanalytical Method Development: The development and validation of bioanalytical methods for monitoring drug interactions and metabolism extensively utilize Tizanidine-D₄ HCl. The isotopic labeling aids in accurate quantification and identification, enhancing the reliability of pharmacokinetic and pharmacodynamic studies (Chen et al., 2024).


• Tizanidine-D₄ Hydrochloride Solution for Receptor Binding Studies: The application of Tizanidine-D₄ in receptor binding studies is inferred from research exploring its withdrawal effects and the pharmacological interventions required, suggesting its utility in detailed receptor interaction studies in clinical settings (Tanimura et al., 2024).

Analysis Note

Colour (visual): white to off white
Appearance of substance (visual): powder
Colour index (0,5 M in DMF): ≤ 150 Hazen
Identity (IR): passes test
Enantiomeric purity: ≥ 99.8 % (a/a)
Purity (HPLC): ≥ 99.0 % (a/a)
Fmoc-ß-Ala-OH (HPLC): ≤ 0.1 % (a/a)
Fmoc-ß-Ala-Lys(Boc)-OH (HPLC): ≤ 0.1 % (a/a)
Fmoc-Lys(Boc)-Lys(Boc)-OH (HPLC): ≤ 0.1 % (a/a)
Fmoc-Lys-OH (HPLC): ≤ 0.1 % (a/a)
Assay free amino acid (GC): ≤ 0.2 %
Purity (TLC(011A)): ≥ 98 %
Purity (TLC(0811)): ≥ 98 %
Solubility (25 mmole in 50 ml DMF): clearly soluble
Assay (acidimetric): ≥ 98.0 %
Water (K. F.): ≤ 2.0 %
Ethyl acetate (HS-GC): ≤ 0.5 %
Acetate (IC): ≤ 0.02 %

To see the solvent systems used for TLC of Novabiochem^® products please click here.

Other Notes

Replaces: 04-12-1026

Legal Information

Novabiochem is a registered trademark of Merck KGaA, Darmstadt, Germany

Información de seguridad

• Clase de almacenamiento: 11 - Combustible Solids
• wgk: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable